🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

A Global Challenge

The sexually transmitted infection are increasing around the world, with estimates suggesting more than 82 million new cases annually. Notably increased rates are reported in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This medication, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Data and Worldwide Availability

As per results released by a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which combines an injection and a pill. The study involved over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians treating patients have voiced positive views. Access to a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is considered crucial to lessen the impact of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.